Fast reaction and long duration—application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report

Abstract

The prognosis of patients with advanced melanoma is poor. The five-year recurrence rate is approximately 70%, whereas the overall survival rate is only 4%–10%. We report the case of a 61-year-old male patient with metastatic melanoma (B-Raf+). The tumor load of the patient was significantly reduced after the application of dabrafenib plus trametinib (“D+T”) and radiotherapy. Further, it is suggested that medical staff should conduct a comprehensive analysis of the patient’s condition when dealing with adverse events (AEs) associated with such malignant tumors to provide evidence for adopting the appropriate targeted treatment or radiotherapy and nursing mode and achieve the best treatment effect.

Keywords

• Melanoma
• B-Raf gene mutation
• Targeted therapy
• Dabrafenib plus trametinib